



**OOG Business Meeting-  
Saturday 30th September 2017, 10:00am**

**1. Welcome:**

The Ophthalmic Oncology Group (OOG) Business Meeting convened at the earlier time of 10am, and was chaired by the OOG Committee: Steven Heegaard (SH), Alexandre Moulin (AM), Robert Verdijk (RV), and Jean-Pierre Caujolle (JPC). The group welcomed everyone to the 52<sup>nd</sup> OOG Meeting.

**2. Approval of Minutes:**

The committee approved the minutes from the last meeting in Athens.

**3. Finances:**

RV provided an overview of the OOG finances. He confirmed that the PayPal account has now closed. The original French account remains open. Payment dues and conference fees should therefore be paid directly to the OOG Treasurer via bank transfer to this account or in person at meetings. Easy instructions will be made available online. RV will provide a full financial overview in Sienna, March 2018. This new system will make transactions more transparent and easier to monitor.

A list of paid members will be added to the new OOG website by Dawn Kohler.

**4. Candidate Members:**

The following members were approved for full membership: Lauge Hjorth Mikkelsen  
Luna Djirackor, Liverpool, is also eligible for membership, and will be proposed again in Sienna.

**5. Future meeting:**

- **SIENNA, ITALY 2018:**

Doris Haudjistilianou presented detailed plans for the next OOG meeting to the committee in Sienna- 21-24 March 2018. Registration fees will be in the region of 200 Euro for the OOG meeting and 230 Euro for the OOG/ EURTB meeting. A social dinner will be organised. The non-membership rate will be 250 Euro. SH highlighted that a YIN programme must also be built into the programme. Doris will begin work on this.

All registration payments need to be made to the OOG treasurer via bank transfer to the OOG account at the moment of registration, prior to the meeting. Abstracts will not be considered without payment.

- **UNITED KINGDOM, 2019:**

Dr Gordon Hay from Moorfields hospital presented a proposal for the 2019 meeting in the United Kingdom. GH offered 2 location options of either London or Cambridge, and the board and committee discussed the cost and travel implications of both locations. Through a show of hands, the general consensus was that Oxford could be an excellent alternative location, and an area which has not been visited before. GH will investigate all options and present his findings at the Siena Business Meeting next year.

## **Future proposals:**

- Tel Aviv, Israel: 2020

Several cities were suggested as potential future locations for OOG meetings including Paris, Edinburgh and Lausanne.

## **6. Website:**

AM and DK provided an overview of the new OOG website: <https://oogeu.weebly.com/>

This is a free site via Weebly, and is a cheaper option than the original website. It was agreed that DK will look at creating a private members area with a generic password for all members. The new site will be user friendly and easy to read. Key information will be on the home page.

## **7. Collaborative studies:**

SH received a proposal from Sarah Coupland in Liverpool regarding uveal melanoma prognostication. Please contact SEC directly for further details: [s.e.coupland@liverpool.ac.uk](mailto:s.e.coupland@liverpool.ac.uk)

Cindy Chau from the Netherlands presented a *BAP1* germline mutation study aiming to assess the association between the genotype and phenotype of *BAP1* germline mutations as well as the management guidelines for *BAP1* germline mutation carriers. Please email Prof Luyten if interested. SH asked Cindy to send the protocol and we will circulate it.

RV presented his proposal for collaborative study on medulloepithelioma. He is looking for studies from well documented patients, looking at histology. Details have been circulated and will be included on the new website.

DK will circulate all of the study proposals again.

## **8. AOB:**

RV reminded members to please pay dues. DK will follow this up with an email to everyone.

OOG has been given a slot at the World Ophthalmology Congress that will be held in June 2018 in Barcelona. The session title will be "controversies in the management of Retinoblastoma" and has been organized by Francis Munier and AM. Martine Jager suggested the possibility to have courses, please submit ideas for 4-6 speakers and purpose of course.

Finally, SH thanked everyone for attending and officially closed the meeting.